Clinical Trials

Date: 2022-03-22

Type of information: Clinical trial authorisation

phase: 1

Announcement: clinical trial authorization

Company: Atrogi

Product: ATR-258

Action mechanism: small molecule ATR-258 is based on ground-breaking research into adrenergic signaling by Professor Tore Bengtsson at Stockholm University leading to the discovery of how to selectively stimulate b2-adrenergic receptors to translocate glucose transporter 4 (GLUT4) to the cell membrane. This promotes glucose uptake in skeletal muscle resulting in a reduction of blood glucose levels achieved without insulin. Atrogi believes ATR-258 has the potential to produce a frontline treatment for type 2 diabetes that produces minimal side effects.

Disease: type 2 diabetes

Therapeutic area: Metabolic diseases

Country: Germany

Trial details: The Phase I protocol covers three parts, Part A: Single Ascending Dose of the drug candidate given to healthy volunteers, Part B: Multiple Ascending Dose administered to healthy volunteers and Part C: continuous administration of xxxx at a fixed dose during 28 days in patients with type 2 diabetes. Eligible Diabetes patients should have a HbA1c level of 7-9% after a Metformin wash-out period over 4 weeks.

Latest news:

  • On March 22, 2022, Atrogi, an early-stage Swedish biopharma company developing a novel solution for the treatment of type 2 diabetes, announced that it has received approval from the German authorities BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023.

Is general: Yes